Endocannabinoids protect the rat isolated heart against ischaemia

The purpose of this study was to determine whether endocannabinoids can protect the heart against ischaemia and reperfusion. Rat isolated hearts were exposed to low‐flow ischaemia (0.5–0.6 ml min −1 ) and reperfusion. Functional recovery as well as CK and LDH overflow into the coronary effluent were monitored. Infarct size was determined at the end of the experiments. Phosphorylation levels of p38, ERK1/2, and JNK/SAPK kinases were measured by Western blots. None of the untreated hearts recovered from ischaemia during the reperfusion period. Perfusion with either 300 n M palmitoylethanolamide (PEA) or 300 n M 2‐arachidonoylglycerol (2‐AG), but not anandamide (up to 1 μ M ), 15 min before and throughout the ischaemic period, improved myocardial recovery and decreased the levels of coronary CK and LDH. PEA and 2‐AG also reduced infarct size. The CB 2 ‐receptor antagonist, SR144528, blocked completely the cardioprotective effect of both PEA and 2‐AG, whereas the CB 1 ‐receptor antagonist, SR141716A, blocked partially the effect of 2‐AG only. In contrast, both ACEA and JWH015, two selective agonists for CB 1 ‐ and CB 2 ‐ receptors, respectively, reduced infarct size at a concentration of 50 n M . PEA enhanced the phosphorylation level of p38 MAP kinase during ischaemia. PEA perfusion doubled the baseline phosphorylation level of ERK1/2, and enhanced its increase upon reperfusion. The cardioprotective effect of PEA was completely blocked by the p38 MAP kinase inhibitor, SB203580, and significantly reduced by the ERK1/2 inhibitor, PD98059, and the PKC inhibitor, chelerythrine. In conclusion, endocannabinoids exert a strong cardioprotective effect in a rat model of ischaemia–reperfusion that is mediated mainly through CB 2 ‐receptors, and involves p38, ERK1/2, as well as PKC activation.British Journal of Pharmacology (2003) 139 , 805–815. doi: 10.1038/sj.bjp.0705313